Thrombocytopenia

• 

  Subject Areas on Research

  • A comparison of bivalirudin to heparin with protamine reversal in patients undergoing cardiac surgery with cardiopulmonary bypass: the EVOLUTION-ON study. 
  • A conundrum: general or neuraxial anesthesia and the use of ROTEM. 
  • A mouse model for heparin-induced thrombocytopenia. 
  • A multicenter, phase II study of maintenance azacitidine in older patients with acute myeloid leukemia in complete remission after induction chemotherapy. 
  • A national assessment of the epidemiology of severe fever with thrombocytopenia syndrome, China. 
  • A national study of the complications of lupus in pregnancy. 
  • A phase I trial of ifosfamide, mesna, and cisplatin in advanced non-small cell lung cancer. A cancer and leukemia group B study. 
  • A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. 
  • A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 
  • A randomized, controlled trial of platelet transfusions in thrombocytopenic premature infants. 
  • A rapid method to isolate platelets from human blood by density gradient centrifugation. 
  • ASFA Category IV becomes Category I: Idiopathic thrombotic thrombocytopenic purpura in a patient with presumed gemcitabine-induced thrombotic microangiopathy. 
  • ASH evidence-based guidelines: is the IgG-specific anti-PF4/heparin ELISA superior to the polyspecific ELISA in the laboratory diagnosis of HIT? 
  • Abciximab readministration: results of the ReoPro Readministration Registry. 
  • Acute profound thrombocytopenia after C7E3 Fab (abciximab) therapy. 
  • Acute profound thrombocytopenia after c7E3 Fab therapy. 
  • Adjunctive agents in systemic chemotherapy. 
  • Adjuvant chemotherapy in primary treatment of osteogenic sarcoma. A Southwest Oncology Group study. 
  • Adriamycin in the treatment of childhood solid tumors. A Southwest Oncology Group study. 
  • Alloimmune thrombocytopenia may be associated with systemic disease. 
  • Alterations in polyamine metabolism during continuous intravenous infusion of alpha-difluoromethylornithine showing correlation of thrombocytopenia with alpha-difluoromethylornithine plasma levels. 
  • Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. 
  • Amelioration of thrombocytopenia with concomitant ornithine in sarcoma-bearing rats receiving high dose difluoromethylornithine. 
  • An open-label phase 2 study of glycogen synthase kinase-3 inhibitor LY2090314 in patients with acute leukemia. 
  • Anti-heparin/platelet factor 4 antibody optical density values and the confirmatory procedure in the diagnosis of heparin-induced thrombocytopenia. 
  • Antibodies from patients with heparin-induced thrombocytopenia stimulate monocytic cells to express tissue factor and secrete interleukin-8. 
  • Anticoagulation techniques in apheresis: from heparin to citrate and beyond. 
  • Anticoagulation therapy. 
  • Antifibrinolytic therapy in the management of the Kasabach Merritt syndrome. 
  • Antithrombotic therapy in heparin-induced thrombocytopenia: guidelines translated for the clinician. 
  • Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. 
  • Argatroban for anticoagulation during cardiopulmonary bypass in an infant. 
  • Association between bone marrow dosimetric parameters and acute hematologic toxicity in anal cancer patients treated with concurrent chemotherapy and intensity-modulated radiotherapy. 
  • Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients. 
  • Atomic description of the immune complex involved in heparin-induced thrombocytopenia. 
  • Autosomal dominant macrothrombocytopenia with leukocyte inclusions (May-Hegglin anomaly) is linked to chromosome 22q12-13. 
  • Beyond thrombosis: the versatile platelet in critical illness. 
  • Bilateral adrenal hemorrhage: the unrecognized cause of hemodynamic collapse associated with heparin-induced thrombocytopenia. 
  • Bilateral macular vitelliform lesions in a thrombocytopenic patient. 
  • Bivalirudin in patients with heparin-induced thrombocytopenia undergoing percutaneous coronary intervention. 
  • Bivalirudin: a review of the pharmacology and clinical application. 
  • Bleeding in acute coronary syndromes. 
  • Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. 
  • Capsule endoscopy performed across the pediatric age range: indications, incomplete studies, and utility in management of inflammatory bowel disease. 
  • Cesarean delivery for fetal malformations. 
  • Characterization of a murine monoclonal antibody that mimics heparin-induced thrombocytopenia antibodies. 
  • Chronic immune-mediated thrombocytopenia after varicella infection. 
  • Clinical challenges of platelet glycoprotein IIb/IIIa receptor inhibitor therapy: bleeding, reversal, thrombocytopenia, and retreatment. 
  • Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockade. 
  • Clinical importance of thrombocytopenia occurring in the hospital phase after administration of thrombolytic therapy for acute myocardial infarction. The Thrombolysis and Angioplasty in Myocardial Infarction Study Group. 
  • Clinical outcomes in a cohort of patients with heparin-induced thrombocytopenia. 
  • Clinical practice. Heparin-induced thrombocytopenia. 
  • Clinical significance of thrombocytopenia during a non-ST-elevation acute coronary syndrome. The platelet glycoprotein IIb/IIIa in unstable angina: receptor suppression using integrilin therapy (PURSUIT) trial experience. 
  • Coagulation and fibrinolytic protein kinetics in cardiopulmonary bypass. 
  • Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. 
  • Comparison of PF4/heparin ELISA assay with the 14C-serotonin release assay in the diagnosis of heparin-induced thrombocytopenia. 
  • Congenital hemophagocytic lymphohistiocytosis presenting as thrombocytopenia in a newborn. 
  • Contribution of bleeding and thromboembolic events to in-hospital mortality among patients with thrombocytopenia treated with heparin. 
  • Critical role for mouse marginal zone B cells in PF4/heparin antibody production. 
  • Cyclophosphamide in combination with sargramostim for treatment of recurrent medulloblastoma. 
  • Cytomegalovirus infection in the normal host. 
  • DTIC, CCNU, bleomycin and vincristine (BOLD) in metastatic melanoma. 
  • Defining a second epitope for heparin-induced thrombocytopenia/thrombosis antibodies using KKO, a murine HIT-like monoclonal antibody. 
  • Defining an antigenic epitope on platelet factor 4 associated with heparin-induced thrombocytopenia. 
  • Diagnosis and management of heparin-induced thrombocytopenia. 
  • Differentiating thrombotic microangiopathies induced by severe hypertension from anemia and thrombocytopenia seen in thrombotic thrombocytopenia purpura. 
  • Disruption of PF4/H multimolecular complex formation with a minimally anticoagulant heparin (ODSH). 
  • Distinct specificity and single-molecule kinetics characterize the interaction of pathogenic and non-pathogenic antibodies against platelet factor 4-heparin complexes with platelet factor 4. 
  • Diuretic exposure in premature infants from 1997 to 2011. 
  • Dose intensity and hematologic toxicity in older breast cancer patients receiving systemic chemotherapy. 
  • Dose of prophylactic platelet transfusions and prevention of hemorrhage. 
  • Dose-finding, safety, and tolerability study of an oral platelet glycoprotein IIb/IIIa inhibitor, lotrafiban, in patients with coronary or cerebral atherosclerotic disease. 
  • Durable engraftment and correction of hematological abnormalities in children with congenital amegakaryocytic thrombocytopenia following myeloablative umbilical cord blood transplantation. 
  • Dynamic antibody-binding properties in the pathogenesis of HIT. 
  • Economic assessment of thrombocytopenia: CATCH Registry. 
  • Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. 
  • Efficacy of abciximab readministration in coronary intervention. 
  • Eltrombopag for thrombocytopenia in patients with cirrhosis associated with hepatitis C. 
  • Endoscopic management of gastrointestinal bleeding from multifocal lymphangioendotheliomatosis with thrombocytopenia: limited efficacy and complications. 
  • Endothelial antigen assembly leads to thrombotic complications in heparin-induced thrombocytopenia. 
  • Eptifibatide and low-dose tissue plasminogen activator in acute myocardial infarction: the integrilin and low-dose thrombolysis in acute myocardial infarction (INTRO AMI) trial. 
  • Etiology and complications of thrombocytopenia in hospitalized medical patients. 
  • Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients: The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. 
  • Evaluation of dose requirements for prolonged bivalirudin administration in patients with renal insufficiency and suspected heparin-induced thrombocytopenia. 
  • Evaluation of the WHO 2009 classification for diagnosis of acute dengue in a large cohort of adults and children in Sri Lanka during a dengue-1 epidemic. 
  • Evidence for genetic homogeneity in a familial platelet disorder with predisposition to acute myelogenous leukemia (FPD/AML) 
  • Expanding the phenotype of multifocal lymphangioendotheliomatosis with thrombocytopenia. 
  • Fatal Rocky Mountain spotted fever. Hematologic and lymphoreticular observations. 
  • Fc gamma RIIA H/R 131 polymorphism, subclass-specific IgG anti-heparin/platelet factor 4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. 
  • Feasibility and safety of moderate hypothermia after massive hemispheric infarction. 
  • Final results of the ReoPro readministration registry. 
  • Fondaparinux therapy in a hemodialysis patient with heparin-induced thrombocytopenia type II. 
  • Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosis. 
  • Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804. 
  • Genome-Wide Association Study Links Receptor Tyrosine Kinase Inhibitor Sprouty 2 to Thrombocytopenia after Coronary Artery Bypass Surgery. 
  • Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. 
  • Genotype-phenotype correlation in MYH9-related thrombocytopenia. 
  • HIV-1-associated thrombocytopenia. The role of splenectomy. 
  • Hematologic toxicity of high-dose iodine-131-metaiodobenzylguanidine therapy for advanced neuroblastoma. 
  • Heparin induced thrombocytopenia: diagnosis and contemporary antithrombin management. 
  • Heparin-Induced Thrombocytopenia: A Review for Cardiac Anesthesiologists and Intensivists. 
  • Heparin-associated antiplatelet antibodies increase morbidity and mortality in hemodialysis patients. 
  • Heparin-dependent platelet factor 4 antibodies and the impact of renal function on clinical outcomes: a retrospective study in hospitalized patients. 
  • Heparin-induced thrombocytopenia and thrombosis. 
  • Heparin-induced thrombocytopenia in cancer. 
  • Heparin-induced thrombocytopenia in left ventricular assist device bridge-to-transplant patients. 
  • Heparin-induced thrombocytopenia in the pediatric intensive care unit population. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia. 
  • Heparin-induced thrombocytopenia/thrombosis in a transgenic mouse model requires human platelet factor 4 and platelet activation through FcgammaRIIA. 
  • Heparin-induced thrombocytopenia: an autoimmune disorder regulated through dynamic autoantigen assembly/disassembly. 
  • Heparin-induced thrombocytopenia: an increasingly common cause of bilateral adrenal hemorrhage. 
  • Heparin-induced thrombocytopenia: bovine versus porcine heparin in cardiopulmonary bypass surgery. 
  • Heparin-induced thrombocytopenia: clinical presentations and therapeutic management. 
  • Heparin-induced thrombocytopenia: pathophysiology and management. 
  • Heparin-induced thrombocytopenia: research and clinical updates. 
  • Heparin-induced thrombocytopenia: twenty-nine years later. 
  • Heparin-induced thrombocytopenia: when a low platelet count is a mandate for anticoagulation. 
  • Hereditary thrombotic thrombocytopenic purpura: microangiopathic hemolytic anemia, thrombocytopenia, and renal insufficiency occurring in consecutive generations. 
  • High incidence of antibodies to protamine and protamine/heparin complexes in patients undergoing cardiopulmonary bypass. 
  • High-dose doxorubicin, dexrazoxane, and GM-CSF in malignant mesothelioma: a phase II study-Cancer and Leukemia Group B 9631. 
  • High-dose factor VIIa increases initial thrombin generation and mediates faster platelet activation in thrombocytopenia-like conditions in a cell-based model system. 
  • Higher doses of mitoxantrone among men with hormone-refractory prostate carcinoma: a Cancer and Leukemia Group B study. 
  • How I treat catastrophic thrombotic syndromes. 
  • How I treat thrombocytopenia in pregnancy. 
  • Human thrombocytopenia is associated with structural abnormalities of the endothelium that are ameliorated by glucocorticosteroid administration. 
  • Hypercoagulable states: a review. 
  • IVIG therapy in neonatal isoimmune thrombocytopenic purpura and alloimmunization thrombocytopenia. 
  • Identification, diagnosis and treatment of heparin-induced thrombocytopenia and thrombosis: a registry of prolonged heparin use and thrombocytopenia among hospitalized patients with and without cardiovascular disease. The Complication After Thrombocytopenia Caused by Heparin (CATCH) Registry steering committee. 
  • Idiopathic monoclonal (IgA) gammopathy in a dog. 
  • Immune fever in the rabbit: responses of the hematologic and complement systems. 
  • Immune pathogenesis of heparin-induced thrombocytopenia. 
  • Immune thrombocytopenia due to Trimethoprim-Sulfamethoxazole; under-recognized adverse drug reaction in children? 
  • Immunotherapy of murine leukemia. II. Effect of passive serum therapy on Friend murine leukemia virus-induced hematologic and coagulation parameters. 
  • Impact of encephalopathy on mortality in the sepsis syndrome. The Veterans Administration Systemic Sepsis Cooperative Study Group. 
  • Impact of in-hospital acquired thrombocytopenia in patients undergoing primary angioplasty for acute myocardial infarction. 
  • Incidence and clinical consequences of acquired thrombocytopenia after antithrombotic therapies in patients with acute coronary syndromes: results from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial. 
  • Incidence and prognostic significance of thrombocytopenia developed during acute coronary syndrome in contemporary clinical practice. 
  • Incidence and prognostic significance of thrombocytopenia in patients treated with prolonged heparin therapy. 
  • Incidence of thrombocytopenia among patients receiving heparin venous thromboembolism prophylaxis. 
  • Inflammation does not predispose to bleeding in hemophilia. 
  • Intensity-modulated radiation therapy for anal malignancies: a preliminary toxicity and disease outcomes analysis. 
  • Intensive single-agent mitoxantrone for metastatic breast cancer. 
  • Is the incidence of heparin-induced thrombocytopenia affected by the increased use of heparin for VTE prophylaxis? 
  • Isoantibody specificity in post-transfusion purpura. 
  • Kasabach-merritt phenomenon: a retrospective study of treatment with vincristine. 
  • Long-term outcomes associated with hospital acquired thrombocytopenia among patients with non-ST-segment elevation acute coronary syndrome. 
  • Maintenance Sunitinib following Initial Platinum-Based Combination Chemotherapy in Advanced-Stage IIIB/IV Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study-CALGB 30607 (Alliance). 
  • Management of human immunodeficiency virus-associated thrombocytopenia with intravenous gamma globulin. 
  • Management of immune dysfunction after adult cardiac surgery. 
  • Management of lepirudin therapy for a patient with antiphospholipid antibody syndrome using the whole blood ecarin clot time and activated partial thromboplastin time. 
  • Management of menorrhagia associated with chemotherapy-induced thrombocytopenia in women with hematologic malignancy. 
  • Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery. 
  • Metastatic angiosarcoma with thrombocytopenia and intratumoral indium-111-platelet deposition. 
  • Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia. 
  • Modulation of O6-alkylguanine-DNA alkyltransferase-mediated carmustine resistance using streptozotocin: a phase I trial. 
  • Monitoring direct thrombin inhibitors: time for standardization. 
  • Mouse models of MYH9-related disease: mutations in nonmuscle myosin II-A. 
  • Mullerian agenesis and thrombocytopenia absent radius syndrome: a case report and review of syndromes associated with Mullerian agenesis. 
  • Multinational, double-blind, phase III study of prednisone and either satraplatin or placebo in patients with castrate-refractory prostate cancer progressing after prior chemotherapy: the SPARC trial. 
  • Multiple innate inflammatory responses induced after systemic adenovirus vector delivery depend on a functional complement system. 
  • Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomaly. 
  • Myelotoxicity from chemotherapy. 
  • Natural history of nonimmune-mediated thrombocytopenia and acute kidney injury in pediatric open-heart surgery. 
  • Nelarabine induces complete remissions in adults with relapsed or refractory T-lineage acute lymphoblastic leukemia or lymphoblastic lymphoma: Cancer and Leukemia Group B study 19801. 
  • New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents. 
  • New treatment options for heparin-induced thrombocytopenia. 
  • Non-cirrhotic thrombocytopenic patients with hepatitis C virus: Characteristics and outcome of antiviral therapy. 
  • Novel diagnostic assays for heparin-induced thrombocytopenia. 
  • Occurrence and clinical significance of pseudothrombocytopenia during abciximab therapy. 
  • Occurrence and clinical significance of thrombocytopenia in a population undergoing high-risk percutaneous coronary revascularization. Evaluation of c7E3 for the Prevention of Ischemic Complications (EPIC) Study Group. 
  • PF4-HIT antibody (KKO) complexes activate broad innate immune and inflammatory responses. 
  • PF4/heparin complexes are T cell-dependent antigens. 
  • PF4/heparin-antibody complex induces monocyte tissue factor expression and release of tissue factor positive microparticles by activation of FcγRI. 
  • Parenteral anticoagulation with the heparinoid Lomoparan (Org 10172) in patients with heparin induced thrombocytopenia and thrombosis. 
  • Pathogenesis of heparin-induced thrombocytopenia and thrombosis. 
  • Pathogenicity of human anti-platelet factor 4 (PF4)/heparin in vivo: generation of mouse anti-PF4/heparin and induction of thrombocytopenia by heparin. 
  • Paving the way for improved management of severe immune thrombocytopenia purpura in pregnancy. 
  • Pearls & Oy-sters: multiple ischemic strokes secondary to heparin-induced thrombocytopenia. 
  • Pediatric large-volume leukapheresis: a single institution experience with heparin versus citrate-based anticoagulant regimens. 
  • Percutaneous coronary interventions in patients with heparin-induced thrombocytopenia. 
  • Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodies. 
  • Perioperative blood transfusion and blood conservation in cardiac surgery: the Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists clinical practice guideline. 
  • Persistent thrombocytopaenia in a young man with splenomegaly, rebound thrombocytosis after splenectomy and subsequent pulmonary embolism: splenic littoral cell angioma and associated events. 
  • Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. 
  • Phase I and clinical pharmacology study of trimetrexate administered weekly for three weeks. 
  • Phase I clinical and plasma and cellular pharmacological study of topotecan without and with granulocyte colony-stimulating factor. 
  • Phase I evaluation of mitoxantrone alone and combined with whole body hyperthermia in dogs with lymphoma. 
  • Phase I study of Gliadel wafers plus temozolomide in adults with recurrent supratentorial high-grade gliomas. 
  • Phase I trial of recombinant human gamma-interferon and recombinant human tumor necrosis factor in patients with advanced gastrointestinal cancer. 
  • Phase I/II dose escalation study of recombinant human interleukin-11 following ifosfamide, carboplatin and etoposide in children, adolescents and young adults with solid tumours or lymphoma: a clinical, haematological and biological study. 
  • Phase I/II study of preoperative oxaliplatin, fluorouracil, and external-beam radiation therapy in patients with locally advanced rectal cancer: Cancer and Leukemia Group B 89901. 
  • Phase II study of (90)Y Ibritumomab tiuxetan (Zevalin) in patients with previously untreated marginal zone lymphoma. 
  • Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma. 
  • Phase II study of carboplatin (CBDCA) in refractory multiple myeloma. A Southwest Oncology Group study. 
  • Plasmapheresis and heparin reexposure as a management strategy for cardiac surgical patients with heparin-induced thrombocytopenia. 
  • Platelet count in deep saturation diving. 
  • Platelet factor 4-heparin complexes trigger immune responses independently of the MyD88 pathway. 
  • Platelets from thrombocytopenic ponies acutely infected with equine infectious anemia virus are activated in vivo and hypofunctional. 
  • Posttransfusion thrombocytopenia: a cautionary tale of female group AB plasma. 
  • Posttransplant autoimmune hemolytic anemia and other autoimmune cytopenias are increased in very young infants undergoing unrelated donor umbilical cord blood transplantation. 
  • Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. 
  • Pregnancy in patients with thrombocytopenia and absent radii (TAR) syndrome. 
  • Profound inhibition of platelet aggregation with monoclonal antibody 7E3 Fab after thrombolytic therapy. Results of the Thrombolysis and Angioplasty in Myocardial Infarction (TAMI) 8 Pilot Study. 
  • Prospective comparison of hemorrhagic complications after treatment with enoxaparin versus unfractionated heparin for unstable angina pectoris or non-ST-segment elevation acute myocardial infarction. 
  • Protamine-induced immune thrombocytopenia. 
  • RNA aptamers as reversible antagonists of coagulation factor IXa. 
  • Readministration of abciximab: interim report of the ReoPro readministration registry. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Reduction of difluoromethylornithine-induced thrombocytopenia in rats with ornithine while maintaining antitumor activity. 
  • Report of a young girl with MYH9 mutation and review of the literature. 
  • Rifampin use and safety in hospitalized infants. 
  • Risk of heparin-induced thrombocytopenia from heparin-bonded vascular prostheses. 
  • Roentgenographic abnormalities in Rocky Mountain Spotted Fever. 
  • Role of complement in the pathophysiology of hematologic diseases. 
  • Role of growth factors and thrombopoietic agents in the treatment of chronic hepatitis C. 
  • Role of platelet surface PF4 antigenic complexes in heparin-induced thrombocytopenia pathogenesis: diagnostic and therapeutic implications. 
  • Safety and efficacy of abciximab combined with dalteparin in treatment of acute coronary syndromes. 
  • Safety of High-dose Acyclovir in Infants With Suspected and Confirmed Neonatal Herpes Simplex Virus Infections. 
  • Safety of milrinone use in neonatal intensive care units. 
  • Safety of octreotide in hospitalized infants. 
  • Secondary failure of platelet recovery after hematopoietic stem cell transplantation. 
  • Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival. 
  • Six-month follow-up of patients with in-hospital thrombocytopenia during heparin-based anticoagulation (from the Complications After Thrombocytopenia Caused by Heparin [CATCH] registry). 
  • Studies of the biologic effects of selective C4 deficiency. 
  • Techniques and applications of perioperative therapeutic plasma exchange. 
  • The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion. 
  • The anticoagulant therapy with bivalirudin to assist in the performance of percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (ATBAT) study: main results. 
  • The antigenic complex in HIT binds to B cells via complement and complement receptor 2 (CD21). 
  • The association of anti-platelet factor 4/heparin antibodies with early and delayed thromboembolism after cardiac surgery. 
  • The effect of drug-induced thrombocytopenia on direct-current transcatheter electrocoagulation. 
  • The relationship of complement consumption to immune fever. 
  • The use of GTX as second-line and later chemotherapy for metastatic pancreatic cancer: a retrospective analysis. 
  • Thrombocytopenia and absent radii (TAR) syndrome associated with horseshoe kidney. 
  • Thrombocytopenia in allogeneic peripheral blood stem cell collections. 
  • Thrombocytopenia in association with a wandering spleen. 
  • Thrombocytopenia in hospitalized patients with severe clostridium difficile infection. 
  • Transplantation-mediated alloimmune thrombocytopenia: Guidelines for utilization of thrombocytopenic donors. 
  • Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial. 
  • Treatment of patients with pineoblastoma with high dose cyclophosphamide. 
  • Ultralarge complexes of PF4 and heparin are central to the pathogenesis of heparin-induced thrombocytopenia. 
  • Ultrastructural analysis of granulocyte inclusions in genetically confirmed MYH9-related disorders. 
  • Umbralisib, a novel PI3Kδ and casein kinase-1ε inhibitor, in relapsed or refractory chronic lymphocytic leukaemia and lymphoma: an open-label, phase 1, dose-escalation, first-in-human study. 
  • Understanding thrombocytopenia and antigenicity with glycoprotein IIb-IIIa inhibitors. 
  • Validation of the high-dose heparin confirmatory step for the diagnosis of heparin-induced thrombocytopenia. 
  • Vincristine therapy for severe platelet alloimmunization. 
  • What is the evidence for platelet transfusion in perioperative settings? 
  • Wide variations in blood product transfusion practices among providers who care for patients with acute leukemia in the United States. 
  • [Malignant melanoma: hepatic intra-arterial chemotherapy]. 
• 

  Keywords of People

  • Arepally, Gowthami Morey, Professor of Medicine, Pathology
  • Granger, Christopher Bull, Professor of Medicine, School of Nursing
  • Hoffman, Maureane Richardson, Professor of Pathology, Immunology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Moon, Richard Edward, Professor of Anesthesiology, Medicine, Pulmonary, Allergy, and Critical Care Medicine
  • O'Connor, Christopher Michael, Richard Sean Stack, M.D. / Guidant Foundation Professor of Cardiology, Medicine, Clinical Pharmacology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Immunology
  • Stinnett, Sandra Sue, Associate Professor of Biostatistics and Bioinformatics, Biostatistics & Bioinformatics
  • Yoo, Sua, Associate Professor of Radiation Oncology, Radiation Oncology